A Phase II Study of PF-04948568(CDX-110) with Radiation and Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme.
Phase of Trial: Phase II
Latest Information Update: 28 Sep 2017
At a glance
- Drugs Rindopepimut (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Therapeutic Use
- Acronyms ACT-III
- Sponsors Celldex Therapeutics
- 05 Jan 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016, according to ClinicalTrials.gov record.
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 28 Feb 2014 Planned End Date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History